THE PSYCHEDELIC AND KETAMINE RENAISSANCE IN THE FACE OF THE CRISIS IN MODERN PSYCHIATRY

Introduction: Contemporary psychiatry is grappling with a profound stagnation in innovation. It is primarily relying on the chronic management of symptoms through traditional daily-dose pharmacotherapy. The emergence of psychedelics and ketamine marks a significant departure from this model. It is offering rapid-acting, interventional alternatives that target the underlying neurobiological mechanisms of mental disorders rather than mere symptom suppression.

Purpose: The primary objective of this article is to evaluate the therapeutic potential of psychedelics and ketamine as catalysts for a new paradigm in mental healthcare. The paper aims to synthesize current knowledge on 5-HT2A receptor agonism, the development of next-generation non-hallucinogenic psychoplastogens, and the ethical-legal challenges associated with implementing these treatments in the global and Polish healthcare systems. Methodology: This study employs a multidisciplinary literature review, integrating recent findings from neuropsychopharmacology, clinical trial outcomes, and bioethical analysis. It compares the efficacy and administration models of classic psychedelics against conventional treatments (e.g., SSRIs) and examines the socioeconomic factors influencing the democratization of these therapies.

Conclusions: The "psychedelic renaissance" necessitates the adoption of a new language for psychiatry, rooted in neuroplasticity and connectivity. To achieve widespread scalability, the field must focus on isolating the plasticity effect and utilizing short-acting tryptamines to reduce clinical resource burdens. Furthermore, for Poland to actively participate in this medical revolution, urgent legislative harmonization and robust ethical frameworks regarding patient suggestibility are required.